Cancer and Antimicrobial Resistance (AMR)

- Antimicrobial resistance happens when microorganisms (such as bacteria, fungi, viruses, and parasites) develop the ability to continue to grow, even when they are exposed to antimicrobial medicines that are meant to kill them or limit their growth (such as antibiotics, antifungals, antivirals, antimalarials, and anthelmintics).
- As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others. While antimicrobial resistance refers to all microbes that resist treatments designed to destroy them, antibiotic resistance specifically deals with bacteria that are resistant to antibiotics.
- Anti-microbial resistance was associated with 4.95 million deaths in 2019 and a reported 1.27 million people died as a direct result of drug-resistant infections and a further.
- By 2050, this number could reach ten million and cost more than USD 100 trillion without collective action.
- If the issue of AMR is not addressed urgently, tens of millions more people will be forced into extreme poverty, hunger and malnutrition.
- Overuse and misuse of anti-microbial medicines are major factors that have contributed to the development of drug-resistant microbes. In many places, antibiotics are overused and misused in people and animals, and often given without professional oversight.
- Examples of misuse include when they are taken by people with viral infections like colds and flu, and when they are given as growth promoters in animals or used to prevent diseases in healthy animals.
- According to a survey by the European Association of Hospital Pharmacists, 63% of hospital pharmacists listed antimicrobial medicines most frequently in shortages, while medicines for cancer were second on the list.
- People with cancer are more susceptible to infections due to the lowering of immune defences, while surgery and treatments like bone marrow transplants, radiotherapy and chemotherapy put the immune system under immense pressure.
- AMR is undermining key advances being made in cancer care by adversely affecting cancer treatment outcomes and threatening the survival of people living with cancer.
- As many as 1 in 5 cancer patients undergoing treatment are hospitalised due to infection, and antibiotics are the main line of defence.
- It is estimated that 8.5% of cancer deaths are due to severe sepsis. Pneumonia and sepsis (as a result of bacterial infection of the blood) are among the most frequent causes of admission to intensive care units for cancer patients.
- A study on AMR in the US estimates that a 30% reduction in the efficiency of antibiotics used for cancer patients (in relation to surgery or chemotherapy) would cause an additional 120,000 infections and 6,300 deaths each year.

See UICC’s dedicated webpage